Literature DB >> 15480897

Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats.

Tadahide Kuroda1, Yutaka Yoshida, Junichi Kamiie, Pavel Kovalenko, Masaaki Nameta, Hidehiko Fujinaka, Eishin Yaoita, Tetsuya Endo, Shunji Ishizuka, Kimimasa Nakabayashi, Akira Yamada, Toshihiko Nagasawa, Tadashi Yamamoto.   

Abstract

BACKGROUND: Matrix metalloproteinase (MMP)-9, a member of the MMP family with specificity towards type IV collagen, is implicated in the turnover of the extracellular matrix in the kidney. To elucidate its physiological and pathophysiological significance, we examined the expression and localization of MMP-9 in the normal kidney and the changes in these features during the course of anti-glomerular basement membrane (GBM) glomerulonephritis induced in WKY rats, along with the changes in these features of tissue inhibitor of metalloproteinase 1 (TIMP-1) and MMP-2.
METHODS: The expression of MMP-9, TIMP-1 and MMP-2 mRNA was quantified by ribonuclease protection assay, and the gelatinolytic activities of MMP-9 and MMP-2 were evaluated by gelatin zymography. The localization of MMP-9 was visualized by immunohistochemistry and immunofluorescence microscopy.
RESULTS: The ribonuclease protection assay indicated the almost exclusive expression of MMP-9 mRNA in the glomerulus of normal kidneys. Immunohistochemistry and double-label immunofluorescence microscopy showed that MMP-9 was localized in the mesangial cells. During the course of anti-GBM glomerulonephritis, the expression of MMP-9 mRNA in glomeruli increased on day 1, peaked on days 3 to 7, and then decreased on day 14. The change in MMP-9 mRNA expression was accompanied by parallel changes in the gelatinolytic activity of the active form of MMP-9, TIMP-1 mRNA expression, and MMP-9 immunoreactivity in mesangial cells. In contrast, glomerular MMP-2 mRNA expression and its activity increased after the decline of MMP-9.
CONCLUSIONS: MMP-9 mRNA was predominantly expressed in the glomerulus in normal rat kidneys and MMP-9 was present in the mesangium. The MMP-9 mRNA expression increased in the glomerulus 3 to 7 days after the induction of anti-GBM glomerulonephritis in WKY rats, in parallel with the development of abnormal glomerular histology and injury, suggesting a role of MMP-9 in proteolysis of the GBM during glomerulonephritis. MMP-2 may participate in the later phase of the nephritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480897     DOI: 10.1007/s10157-004-0289-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  15 in total

1.  Temporal characterization of the development of renal injury in FHH rats and FHH.1BN congenic strains.

Authors:  Jan Michael Williams; Marilyn Burke; Jozef Lazar; Howard J Jacob; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

2.  Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Authors:  Jan M Williams; Jin Zhang; Paula North; Steven Lacy; Michael Yakes; Annette Dahly-Vernon; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

3.  Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.

Authors:  Makiho Sekiuchi; Akihiko Kudo; Kimimasa Nakabayashi; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2012-05-22       Impact factor: 2.801

4.  Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.

Authors:  Tetsuya Endo; Kimimasa Nakabayashi; Makiho Sekiuchi; Tadahide Kuroda; Akinori Soejima; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

5.  Deficient degradation of homotrimeric type I collagen, α1(I)3 glomerulopathy in oim mice.

Authors:  Anna M Roberts-Pilgrim; Elena Makareeva; Matthew H Myles; Cynthia L Besch-Williford; Amanda C Brodeur; Andrew L Walker; Sergey Leikin; Craig L Franklin; Charlotte L Phillips
Journal:  Mol Genet Metab       Date:  2011-07-31       Impact factor: 4.797

6.  Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus.

Authors:  Kathryn M Thrailkill; Cynthia S Moreau; Gael E Cockrell; Chan-Hee Jo; Robert C Bunn; Alba E Morales-Pozzo; Charles K Lumpkin; John L Fowlkes
Journal:  Endocrine       Date:  2010-01-12       Impact factor: 3.633

7.  Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.

Authors:  Anita Gianella; Elena Nobili; Mauro Abbate; Carla Zoja; Paolo Gelosa; Luciana Mussoni; Stefano Bellosta; Monica Canavesi; Daniela Rottoli; Uliano Guerrini; Maura Brioschi; Cristina Banfi; Elena Tremoli; Giuseppe Remuzzi; Luigi Sironi
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 8.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

9.  Protease-activated receptor-2 augments experimental crescentic glomerulonephritis.

Authors:  Leon Moussa; Jim Apostolopoulos; Piers Davenport; Jorge Tchongue; Peter G Tipping
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

10.  Albumin modulates the production of matrix metalloproteinases-2 and -9 in podocytes.

Authors:  Zhan Fang; Fangfang He; Shan Chen; Xifeng Sun; Zhonghua Zhu; Chun Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.